Dcf Advisers, LLC Seagen Inc. Transaction History

Dcf Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $124,481 - $140,504	-650 Reduced 5.58%	11,000 $2.33 Million
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $93,820 - $103,125	-500 Reduced 4.12%	11,650 $2.24 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $38,277 - $60,924	-300 Reduced 2.41%	12,150 $2.46 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $82,159 - $97,418	700 Added 5.96%	12,450 $1.6 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $439,627 - $585,357	-3,250 Reduced 21.67%	11,750 $1.61 Million

Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $179,415 - $236,775	1,500 Added 11.11%	15,000 $2.16 Million
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $1.86 Million - $2.58 Million	13,500 New	13,500 $1.88 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.